Current Report · Items 1.01, 2.03, 9.01 · 8-K
Nexalin Technology, Inc.
NXLNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Investor purchased from the Company an unsecured promissory note in the amount of $1,170,000 (the “Note”), which included an original issue dis…
Filed Aug 21, 2026Accepted Aug 21, 2026, 5:20 PM EDTCIK 1527352Accession 0001829126-26-009226
Company context
We are a medical device company engaged in the design and development of innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.
Current securities
Historical securities (1)
Disclosure sections
Items 1.01, 2.03, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On August 21, 2026, Nexalin Technology, Inc. (the
“Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with an institutional investor
(the “Investor”), pursuant to which the Investor purchased from the Company an unsecured promissory note in the amount of
$1,170,000 (the “Note”), which included an original issue discount of $150,000 (the “OID”) and reimbursement of
the Investor’s transaction expenses of $20,000, for gross proceeds to the Company of $1,000,000 (the “Purchase Price”).
The Note matures six months after the Investor
delivers the Purchase Price to the Company and does not bear interest unless and until an event of default occurs. The Company may prepay
all or any portion of the outstanding balance of the Note at any time without penalty or premium. Each time the Company receives any proceeds
in connection with any fundraising or financing transaction, it must make a mandatory prepayment equal to the lesser of 20% of the amount
raised or the outstanding balance of the Note. On up to two occasions, with the Investor’s consent, the Company may extend the maturity
date by three months, in which case the outstanding balance will automatically increase by 7.5% on the first day of each extension period.
The Note Purchase Agreement and the Note contain
customary agreements, affirmative and restrictive covenants, representations and warranties, and customary trigger events and events of
default. Trigger events include, but are not limited to, failure to pay amounts when due, commencement of bankruptcy or insolvency proceedings,
entering into a fundamental transaction (including certain mergers, acquisitions, and changes of control, as defined in the Note) without
repaying the Note in full at or as a condition to closing, and failure to observe covenants in the Note Purchase Agreement (each, a “Trigger
Event”). Upon the occurrence of a Trigger Event, the Investor may increase the outstanding balance by 10% for Major Trigger Events
(as defined in the Note) and 5% for Minor Trigger Events (as defined in the Note), subject to an aggregate cap of 25%. If a Trigger Event
is not cured within five trading days following notice from the Investor, it becomes an event of default, and the Investor may accelerate
the Note. Upon an event of default, interest accrues at 18% per annum (or the maximum rate permitted by law, if lower) from the date of
the event of default.
The Note Purchase Agreement provides for indemnification
of the Investor and its affiliates in the event that they incur any loss or damage related to, among other things, a breach by the Company
of any of its representations, warranties, or covenants under the Note Purchase Agreement, including advancement of expenses as they are
incurred.
The
description of the Note Purchase Agreement and the Note does not purport to be complete and is qualified in its entirety by the full
text of the Note Purchase Agreement and the Note, copies of which are filed herewith as Exhibits 10.1 and 10.2, respectively, and which
are incorporated herein by reference.
The
representations, warranties and covenants contained in the Note Purchase Agreement and the Note were made only for purposes of such agreement
and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to exceptions and limitations
agreed upon by the contracting parties. Accordingly, the Note Purchase Agreement and the Note are incorporated herein by reference only
to provide investors with information regarding the terms of such agreements, and not to provide investors with any other factual information
regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports
and other filings with the U.S. Securities and Exchange Commission.
Item 2.03Item 2.03 - Creation of Direct Financial Obligation
Item Creation
2.03 of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The
information contained in Item 1.01 above is incorporated by reference in this Item 2.03.